The architecture powering Zero Trust at the edge

Tern plc

The shift to Zero Trust security has placed a new spotlight on the most fundamental yet overlooked layer of the digital ecosystem: device identity. For enterprises managing vast fleets of connected assets, the moment of onboarding is no longer a technical footnote, it is the critical juncture where long-term trust, compliance, and resilience begin.

What has long been treated as an administrative step in the supply chain has now become a strategic control point. Weak or reused device identities have been the unseen entry point for some of the most serious operational breaches, from energy grid outages to compromised medical systems. Yet, the tide is turning. Advances in automated identity provisioning now enable enterprises to establish verifiable trust at the very edge, embedding security directly during manufacturing and onboarding rather than layering it on afterwards.

At the centre of this evolution is Device Authority’s KeyScaler® platform, which automates the creation and management of strong, unique device identities at industrial scale. Each identity can be anchored in hardware through Trusted Platform Modules or secure elements, or dynamically generated via Dynamic Device Key Generation when such components are absent.

The true strength of Zero Trust, however, lies in the ongoing validation of identity rather than its initial establishment. Device Authority’s partnership with Olympus integrates these trust anchors into identity and access management frameworks where policies continuously adapt to device health, behaviour, and operational context.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Device Authority strengthens position in machine identity and Zero Trust Security

Device Authority’s inclusion in two 2026 Gartner Hype Cycle reports reinforces its positioning in machine identity, IoT authentication and Zero Trust security.

Talking Medicines highlights strategic value of patient journey intelligence

Patient journey intelligence can help healthcare organisations identify care barriers and design more responsive pathways around real patient experiences.

Evidence-based care pathways support more consistent healthcare delivery

Evidence-based care pathways can improve diagnosis, treatment consistency and the integration of new therapies into routine care.

Tern increases Talking Medicines funding and raises shareholder distribution commitment

Tern has invested in additional Talking Medicines convertible loan notes and increased its minimum shareholder distribution commitment to 70% on qualifying exits.

Evidence-based care pathways create clearer routes to adoption

Evidence-based care pathways can reduce delays, improve treatment consistency and support the adoption of new therapies.

Talking Medicines highlights the data opportunity emerging around GLP-1 care

Talking Medicines examines how the expanding GLP-1 market is increasing the importance of clear distinctions between approved therapies, compounded medicines and nutritional support.

Search